Sanofi ADR (SNYN)

1,012.89
-32.11(-3.07%)
  • Volume:
    9
  • Bid/Ask:
    1,017.95/1,200.00
  • Day's Range:
    1,012.89 - 1,012.89
  • Type:Equity
  • Market:Mexico
  • ISIN:US80105N1054
  • S/N:80105N105

SNYN Overview

Prev. Close
1,045
Day's Range
1,012.89-1,012.89
Revenue
1.38T
Open
1,012.89
52 wk Range
920-1,197.22
EPS
-
Volume
9
Market Cap
2.56T
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
5,036
P/E Ratio
-
Beta
-
1-Year Change
-9.29%
Shares Outstanding
1,253,308,728
Next Earnings Date
-
What is your sentiment on Sanofi ADR?
or
Market is currently closed. Voting is open during market hours.

Sanofi ADR News

Sanofi ADR Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellBuy
Technical IndicatorsNeutralSellStrong SellStrong SellSell
SummaryNeutralSellStrong SellStrong SellNeutral

Sanofi ADR Company Profile

Sanofi ADR Company Profile

Employees
99412

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration with TrialSpark Inc. to execute clinical research studies in the areas of chronic obstructive pulmonary disease. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.